XOMA Corp (XOMA NASDAQ) stock market data APIs
$37.5999
0.55(1.5%)
as of September 12, 2025
Try our APIs with
free plan!
XOMA Corp Financial Data Overview
Price chart is built with
Anychart
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Prev. Close
37.5999
Open
38.1519
High
38.1519
Low
36.7248
52 wk Range
18.352-38
Market Cap
452 M
Shares Outstanding
12 088 K
Revenue
44 952 K
EPS
0.44
Dividends (Yield)
0
Beta
0.988
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with XOMA Corp (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get XOMA Corp data using free add-ons & libraries
Get XOMA Corp Fundamental Data
XOMA Corp Fundamental data includes:
- Net Revenue: 44 952 K
- EBITDA: -7 345 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.2
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XOMA Corp News
New
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief In...
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Xoma Royalty Corp. is acquiring another struggling bi...
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corpor...
Mural Oncology to be acquired by XOMA unit for up to $2.24/share in cash
* Mural Oncology (NASDAQ:MURA [https://seekingalpha.com/symbol/MURA]) and XOMA Royalty (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]) have entered [https://seekingalpha.com/pr/20206473-mural-o...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
